07:13 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended granting marketing authorization to SciencePharma's insulin aspart drug Garzulys, a biosimilar to Novo Nordisk's (NOVO-B.CO) NovoRapid. Garzulys is intended to treat diabetes mellitus in adults, adolescents and children aged one year and above, according to a Friday notice. The committee's positive opinion is based on data showing that Garzulys has comparable quality, safety and efficacy to NovoRapid, which was authorized in the EU in September 1999. The drug is subject to a final marketing authorization decision by the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.